Here, we describe the characteristics of our novel VLP vaccine platform and demonstrate its efficacy and applicability in the context of the malaria CSP antigen, a major surface antigen expressed on the surface of malaria sporozoites and involved in the initial infective stage by malaria parasites in humans (15). Here, DNAJC5 is linked to malaria.